Science & Pipeline

A new class of precision modulators powering multiple programs across inflammatory and fibrotic diseases.

Indication
Preclinical
Phase 1
Phase 2
Phase 3
Osteoarthritis (OA)
CX-011
Mild to moderate knee OA
Intra-articular injectable suspension
indication_status_phase_1
Idiopathic Pulmonary Fibrosis (IPF)
CX-1015 analog
Inhalable or oral
indication_status_preclinical
Cardiometabolic Diseases
Undisclosed small molecule
Oral
indication_status_preclinical

The Biology of Inflammation

  1. Inflammation plays a central role in disease progression and remains an important therapeutic target across multiple indications.
  2. Patients with osteoarthritis, IPF, cardiometabolic disease and other chronic conditions face persistent unmet clinical need.
  3. The IL-6/gp130 signaling axis is a major contributor to chronic inflammation.
  4. Existing IL-6 antibodies are anti-inflammatory often acting as binary on/off switches that lead to oversuppression of immune function.
  5. A major opportunity exists for therapies that modulate—not block—IL-6/gp130 signaling to preserve beneficial pathways while reducing pathological inflammation.
Primary focus areas include Degenerative Joint Disease (DJD) / Osteoarthritis (OA), Idiopathic Pulmonary Fibrosis (IPF), and Cardiometabolic Diseases

Engineered Signaling Beyond Antibody Therapy

“On/Off” Antibody Therapies Oversuppress Immune Responses

When an antibody binds to its target (e.g. IL-6 or IL-6 receptor), it blocks it completely. All downstream signaling is inhibited.

Modulation Allows Beneficial Signaling

Innata's small molecules redefine inflammation by unlocking tunable outputs downstream of gp130, balancing immune signaling.

Why Target the IL-6/gp130 Axis?

Osteoarthritis (OA) - local intra-articular injection


For information on Innata Bio's clinical trial in progress, please see NCT07308834.
 

Large Unmet Need

No approved therapies that mitigate pain, improve function and halt disease progression

Validated IL-6 Biology

Proven role in cartilage degradation with differentiated local delivery approach.

Clear Regulatory Path

First-in-class opportunity with established pain and imaging endpoints

De-risked Development

Faster proof-of-concept vs. systemic indications
Idiopathic Pulmonary Fibrosis (IPF) - inhalable/oral delivery

Myeloid Cells Drive Fibrosis

Macrophages and monocytes are central to IPF pathogenesis; gp130 is a master regulator of myeloid cell recruitment and activation

IL-6 Family Cytokines Fuel Disease

IL-6 and IL-11 mediated gp130 activation induces fibrogenic signaling and disease progression

Age-driven Innate Immune Dysfunction

IL-6 levels increase with age, impairing innate immune function

Unique First-in-Class Opportunity

Modulation of gp130 signaling induced by IL-6 and IL-11 targets two key fibrogenic signals with one small molecule
Cardiometabolic Diseases - oral delivery

Inflammation Drives Risk

IL-6 is a critical risk factor in cardiometabolic diseases, strongly correlating with mortality

IL-6 Pathway Validation

Recent late-stage clinical trials have demonstrated the clinical benefit of reducing IL-6 levels in cardiometabolic diseases

Validated Biomarkers

These trials and those of NLRP3/inflammasome inhibitors demonstrate reduced cardiometabolic risk based on serum biomarkers including IL-6, hsCRP, Lp(a) and fibrinogen

Unmet Need

Current therapies target IL-6 with mAbs. Small molecules could provide broader access

Platform Expansion

Strategic focus on diseases of inflammation leverages gp130's central role in myeloid cell function, positioning Innata Bio to address key unmet need in multiple diseases